Faellanden, Switzerland, Feb 17: Bruker today announces the release of the B.I.QUANT-UR™ 1.1 module, the only analysis solution on the market that complies with DIN-ISO criteria for the identification and quantification of urine metabolites on Bruker’s nuclear magnetic resonance (NMR) in-vitro diagnostic research (Avance™ IVDr) platforms. The module automatically quantifies up to 150 endogenous and disease-related metabolites from urine, allowing users to obtain precise, sensitive and fully reproducible results, even below the limit of detection (LOD).
NMR produces highly reliable quantification values from a single experiment, which would traditionally require multiple tests with different sample preparations using techniques such as conventional gas chromatography mass spectrometry (GC-MS) or ion exchange chromatography mass spectrometry (IEC-MS). B.I.QUANT-UR 1.1 combines the raw concentration of a compound with quality assessment parameters to obtain reliable quantification results, and has demonstrated great potential in clinical and translational research. The new module introduces two additional parameters to provide confidence in quantification: signal correlation (ρ,%) to characterize the match between the lineshape metabolite signal and the calculated fit, with color coded flags added for improved visualization; and concentration error (Δ,mmol/L), for the concentration equivalent of the difference between metabolite signal and the calculated fit.
A key challenge in quantifying metabolites in urine is the complexity of the sample, which contains thousands of compounds generating multiple NMR signals. A unique feature of B.I.QUANT-UR includes DIN-ISO conformant wet spiking, to identify correct signals where there is significant overlap. This upgraded version of the successful B.I.QUANT-UR 1.0 module represents another iteration of a unique feature known as numerical spiking, where pure compound spectra of all 150 metabolites are automatically added to more than 20,000 urine spectra, and subjected to the quantification algorithm to determine the respective probabilistic LOD.
Dr. Manfred Spraul, CTO of the Applied, Industrial and Clinical (AIC) Division at Bruker BioSpin, commented: “Here we have a fully validated research use only system including DIN-ISO spiking – with which B.I.QUANT-UR 1.1 is fully compatible. With this module, users can go substantially below the LOD to obtain meaningful results and use the two new parameters to judge if the result can be trusted, in order to achieve substantially more quantifications than before.”
For more information about the Bruker B.I.QUANT-UR 1.1, please visit www.bruker.com/products/mr/nmr-preclinical-screening/biquant-ur.html
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology.